CoChat

HNF4α: A New Biomarker in Colon Cancer?

Open access
Chellappa, Karthikeyani, Robertson, Graham R, Sladek, Frances M · 2012 · Biomarkers in Medicine
Cited by 35

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Colorectal cancer (CRC) is the fourth leading cause of cancer-related mortality worldwide with 50,000 deaths related to CRC annually in the USA alone. Early detection (Duke’s stage A) predicts good survival (>90%) among CRC patients while the involvement of lymph nodes (stage C) or metastases (stage D) generally predicts survival below 50 and 10%, respectively. This highlights the need to identify prognostic biomarkers of early stage CRC as well as the need for more effective treatments at later stages. Here, we discuss the growing interest of HNF4α in CRC, as well as its potential as a biomarker for prognosis, susceptibility and treatment of this deadly disease. HNF4α is a highly conserved member of the nuclear receptor superfamily of ligand-dependent transcription factors. It is expressed in the liver, pancreas, kidney, stomach, small intestine and colon, where it regulates many important aspects of epithelial cell morphogenesis and function. Nine different isoforms of HNF4α produced by alternate promoter usage and splicing have been identified thus far. Isoforms HNF4α1–3 are derived from the P1 promoter (P1-HNF4α), whereas HNF4α7–12 are derived from the P2 promoter (P2-HNF4α). The P1- and P2-driven proteins differ by approximately 16–29 amino acids in their N-terminal domain, which encodes an important activation function [101]. HNF4α is best known for its role in the liver and pancreas, including an inherited form of Type 2 diabetes referred to as MODY1, although it is increasingly being linked to liver and colon cancer [1–7]. Expression of P1- and P2-driven HNF4α in adult and embryonic liver, respectively, is essential for hepatocyte function and liver development [101]. Not surprisingly, loss of HNF4α leads to dedifferentiation of hepatocytes; it also leads to a switch from slow-growing to rapidly proliferating aggressive hepatocellular carcinoma (HCC) [1]. Recently HNF4α was identified as a central player in an inflammatory feedback loop involving IL-6 and miRNAs that leads to a decrease in HNF4A expression and an increase in HCC occurence [2]. While such reports do not distinguish between the P1- and P2-HNF4α isoforms, other studies have shown that P1-HNF4α expression is reduced in human and mouse HCC tissues while P2-HNF4α expression is aberrantly activated [6,8]. Taken together, these findings suggest that P1-HNF4α acts as a tumor suppressor in hepatocytes. However, the precise role of P2-HNF4α in HCC, and other cancers, remains to be determined.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2217/bmm.12.23

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • A renaissance for SRC

    Yeatman, T. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1366 · Cited by 1,113 · cited 1×

    “We identified the probable mechanism for the differential loss of nuclear P1-HNF4α by showing that Src tyrosine kinase, a known player in CRC [14], phosphorylates Tyr14 in the HNF4α A/B domain.”
    Background

Show all 1 references

Cited by

See all 35

Metadata

Authors
Chellappa, K., Robertson, G. R., & Sladek, F. M.
Venue
Biomarkers in Medicine
Published
2012-06
Volume
6
Issue
3
Pages
297-300
ISSN
  • 1752-0363 (ISSN-L)
  • 1752-0371
OpenAlex
W2102385563
Cited by
35
References
1
FWCI
1.25
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: HNF4α: A New Biomarker in Colon Cancer? https://app.cochat.ai/papers/10.2217/bmm.12.23
The paper
Chellappa, K., Robertson, G. R., & Sladek, F. M. (2012). HNF4α: A New Biomarker in Colon Cancer? Biomarkers in Medicine. https://doi.org/10.2217/bmm.12.23

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.